Furthermore, a study conducted by Shen et al. [147] confirmed an independent association between a high grade of the pre-treatment serum CRP/ALB ratio combined with pre-treatment serum NLR and worse OS in HCC patients treated with TACE followed by RFA. The gene discussed is ALB; the disease is hepatocellular carcinoma.